Securities code: Joincare Pharmaceutical Group Industry Co.Ltd(600380) securities abbreviation: Joincare Pharmaceutical Group Industry Co.Ltd(600380) Joincare Pharmaceutical Group Industry Co.Ltd(600380)
First quarter report 2022
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and integrity of its contents according to law. Important content tips (I) the company's board of directors, board of supervisors, directors, supervisors and senior managers guarantee that the contents of the quarterly report are true, accurate and complete, and there are no false records, misleading statements or major omissions, and bear individual and joint legal liabilities. （2） The person in charge of the company, the person in charge of accounting and the person in charge of the accounting organization (Accounting Supervisor) ensure that the information in the financial statements in the quarterly report is true, accurate and complete. （3） Are the first quarter financial statements audited
□ yes √ no (IV) the quarterly report is prepared in Chinese and English respectively. In case of any ambiguity between the Chinese and English versions, the Chinese version shall prevail. 1、 Main financial data (I) main accounting data and financial indicators
Unit: yuan currency: RMB
Increase or decrease of the project in the reporting period over the same period of last year (%)
Operating income 465734353889 12.36
Net profit attributable to shareholders of listed company 4 Zhejiang Mustang Battery Co.Ltd(605378) 1353 25.52
Non recurring profits and losses attributable to shareholders of listed companies
Net profit 45719370295 36.47
Net cash flow from operating activities 87190447698 76.27
Basic earnings per share (yuan / share) 0.241128.49
Diluted earnings per share (yuan / share) 0.241028.72
The weighted average return on net assets (%) was 3.84, an increase of 0.58 percentage points
Increase or decrease at the end of the reporting period compared with the end of the previous year (%)
Total assets 3275092753153110390038929 3.77
Ownership attributable to shareholders of listed companies
Owner's equity 12073975596591182029365669 2.15
Note: during the reporting period, the company achieved an operating revenue of 4.657 billion yuan, with a year-on-year increase of 12.36%, mainly due to the stable growth of the sales of main varieties in the company's key specialty fields. In the first quarter of 2022, the operating revenue of chemical agents was 2.737 billion yuan, with a year-on-year increase of 24.54%, of which the revenue of respiratory products was 363 million yuan, with a year-on-year increase of 324.90%; The revenue of anti infection products was 350 million yuan, a year-on-year increase of 26.91%; The revenue of gastrointestinal products was 1.07 billion yuan, a year-on-year increase of 5.90%; The revenue of sex hormone products was 737 million yuan, a year-on-year increase of 22.84%. The revenue of APIs and intermediates was 1.406 billion yuan, a year-on-year increase of 14.90%. The revenue of traditional Chinese medicine preparations was 283 million yuan, a year-on-year decrease of 33.53%. The revenue of diagnostic reagents and equipment was 162 million yuan, a year-on-year decrease of 30.77%. （2） Non recurring profit and loss items and amounts
Unit: yuan currency: RMB
Description of current amount of the project
Gains and losses from disposal of non current assets -37441751 gains from disposal of fixed assets
Government subsidies included in the current profits and losses, but positively related to the company
Government subsidies closely related to regular business and included in current profits and losses in accordance with national policies and regulations
Enjoy 5664488724 in a fixed or fixed amount according to a certain standard
Except for the government subsidies, except for the effective hedging business related to the normal business of the company, it holds trading financial assets and derivatives
The fair value of financial assets, trading financial liabilities, derivative funds, trading financial assets / liabilities, the profit and loss from changes in fair value arising from variable financing liabilities, and the profit and loss of -4527553262, as well as the investment income obtained from holding and disposing of trading financial assets, derivative financial assets and assets / liabilities
Investment income from trading financial liabilities, derivative financial liabilities and other debt investments
Other non operating income and expenses other than the above items 24141542
Less: income tax impact 912466576 income tax impact of the above items
Influence amount of minority shareholders' equity (after tax) -123242381 part of the above items that minority shareholders should enjoy
Total 334411058
Description of defining the non recurring profit and loss items listed in the explanatory announcement on information disclosure of companies offering securities to the public No. 1 - non recurring profit and loss as recurring profit and loss items □ applicable √ not applicable (III) changes in main accounting data and financial indicators, reasons √ applicable □ not applicable
Project name change proportion (%) main reasons
The deduction of non recurring attributable to the shareholders of the listed company is mainly due to the increase of 36.47% of the net profit from the sales profit and loss of chemical agents and API products in the current period, driving the growth of the net profit.
The net cash flow from operating activities was 76.27%, mainly due to the increase in sales receipts in the current period.
（4） Major changes in other accounting statement items and financial indicators and reasons
Unit: yuan currency: RMB
Main reasons for changes in the balance sheet from March 31, 2022 to December 31, 2021
（%）
Short term borrowings 165580790110251848483509 - 34.25 were mainly due to the repayment of borrowings in the current period.
Contract liabilities 1240896323123414070229 - 47.00 are mainly due to the carried forward income of part of the contract payment received in advance in this period when it meets the conditions for revenue recognition.
Tax payable 3825489780827061818341 41.36 is mainly due to the increase of enterprise income tax payable.
The long-term loan 18166618094882678025278 119.73 was mainly due to the new growth period loan of the subsidiary in the current period.
Treasury shares 4725902969622264445450 112.26 were mainly due to share repurchase in the current period.
Other comprehensive income -8749845108538754597 -172409 is mainly the impact of the disposal of Galaxy Securities in the current period.
Main reasons for the change proportion of income statement in the first quarter of 2022 and the first quarter of 2021
（%）
The investment income was 29176808522181273270 33.76, which was mainly due to the increase in the income from associated investment held in the current period.
The change in the fair value of the underlying securities is mainly caused by the change in the market value of the underlying securities held -393939394999 -15118.
